News

. . .

		AboutBoard of directors
Management
Who we are
We build...CompaniesOverview
Internal Portfolio
Companies we’ve helped build
Accelerator
EcosystemsOverview
Innovation Centres
AbbVie Biotech Innovators Award
TalentOverview
Executive Institute
BIS Program
Experiential  Learning
adMare Institute
News
Events
CareersCulture
Open positions
Press Room
Contact us
Newsletter

	

			Terms and conditions
    
Français

		
adMare

News
vertical
adMare newsadMare insightsPortfolio companiesadMare AcademyAccelerator companies

						
						July 21 2026
adMare insights						
Canada has the science. Does it have the strategy to be a life sciences power?   
Read

						
						June 16 2026
adMare news						
adMare Executive Institute Opens Applications for Ninth Cohort 
Read

						
						May 13 2026
adMare news						
VoxCell BioInnovation and adMare BioInnovations Partner to Advance Novel Antibody Therapies in a Human-Relevant Vascularized Tissue Platform
Read

						
						April 30 2026
adMare news						
AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec
Read

						
						April 23 2026
Portfolio companies						
Epitopea Announces Approval of OVACT Clinical Trial Application for CryptiVax-1001 in Advanced High-Grade Serous Ovarian Cancer
Read

						
						April 22 2026
Portfolio companies						
Thryv Therapeutics Commences Patient Dosing in Wave II Clinical Study for Long QT Syndrome and Receives FDA Fast Track Designation for THRV-1268
Read

						
						April 16 2026
adMare news						
adMare BioInnovations Officially Opens M4 Innovation Centre in Vancouver to Support the Growth of Life Sciences Companies in Canada
Read

						
						April 09 2026
Portfolio companies						
Kainova Therapeutics Expands Phase I / II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe
Read

						
						March 31 2026
adMare news						
adMare BioInnovations Leadership Announcement
Read

						
						March 19 2026
Portfolio companies						

Grant to Develop a Machine Learning Platform to Accelerate the Development of the Company's Dualase®-based Therapeutics

Read

						
						March 10 2026
Portfolio companies						
Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors
Read

						
						March 03 2026
adMare news						
New Canadian Biotech 26therapeutics Inc. Targets Root Cause of Dry Eye Disease with First-in-Class Therapy
Read
  1  2  3  4  5  6  7  8  9  10  ...   18
Newsletter

Stay up to date on the

latest adMare news
Subscribe
Français
Vancouver Innovation Centre2405 Wesbrook Mall

Vancouver, British Columbia, Canada

V6T 1Z3
T. 604.364.1220
Toronto OfficeMaRS Centre Heritage Building 

101 College Street, Suite 250

Toronto, Ontario, Canada

M5G 1L7
info@admarebio.com
Montreal Innovation Centre7171 Frederick-Banting

Montréal, Québec, Canada

H4S 1Z9
T. 514.375.3334
We

	build ...
Companies
Ecosystems
Talent
Who we are
adMare Institute
News
Events
Careers
Newsletter
Contact Us
Press Room
  
Français
adMare BioInnovations Année all rights reserved - Privacy policy
Website by Riposte
 

  <img height="1" width="1" style="display:none" alt=""
       src="https://px.ads.linkedin.com/collect/?pid=7577452&fmt=gif" />

                
                    Powered by 
                    
                
            

adMare News

Canada has the science. Does it have the strategy to be a life sciences power?

adMare Executive Institute Opens Applications for Ninth Cohort

VoxCell BioInnovation and adMare BioInnovations Partner to Advance Novel Antibody Therapies in a Human-Relevant Vascularized Tissue Platform

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Epitopea Announces Approval of OVACT Clinical Trial Application for CryptiVax-1001 in Advanced High-Grade Serous Ovarian Cancer

Thryv Therapeutics Commences Patient Dosing in Wave II Clinical Study for Long QT Syndrome and Receives FDA Fast Track Designation for THRV-1268

adMare BioInnovations Officially Opens M4 Innovation Centre in Vancouver to Support the Growth of Life Sciences Companies in Canada

Kainova Therapeutics Expands Phase I / II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe

adMare BioInnovations Leadership Announcement

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

New Canadian Biotech 26therapeutics Inc. Targets Root Cause of Dry Eye Disease with First-in-Class Therapy

Newsletter

Stay up to date on the latest adMare news

Vancouver Innovation Centre

T. 604.364.1220

Toronto Office

info@admarebio.com

Montreal Innovation Centre

T. 514.375.3334

adMare
News

Stay up to date on the
latest adMare news